Drug Report History #175542
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v20-EN | Version v4-EN | |
|---|---|---|
| Language | English | English |
| Date Updated (Changed) | Updated to: 2023-05-12 | Was: 2022-11-25 |
| Drug Identification Number | 02243676 | 02243676 |
| Brand name | RECOMBIVAX HB | RECOMBIVAX HB |
| Common or Proper name | (hepatitis B vaccine [recombinant]) | (hepatitis B vaccine [recombinant]) |
| Company Name | MERCK CANADA INC | MERCK CANADA INC |
| Ingredients | HEPATITIS B SURFACE ANTIGEN | HEPATITIS B SURFACE ANTIGEN |
| Strength(s) | 10MCG | 10MCG |
| Dosage form(s) | SUSPENSION SOLUTION | SUSPENSION SOLUTION |
| Route of administration | INTRAMUSCULAR INTRAMUSCULAR | INTRAMUSCULAR INTRAMUSCULAR |
| Packaging size | 10MCG/1ML 1DOSE VIAL | 10MCG/1ML 1DOSE VIAL |
| Additional packaging sizes | ||
| ATC code | J07BC | J07BC |
| ATC description | VIRAL VACCINES | VIRAL VACCINES |
| Reason for shortage | Demand increase for the drug. | Demand increase for the drug. |
| Anticipated start date (Changed) | Updated to: 2022-12-02 | Was: 2022-11-24 |
| Actual start date (Changed) | Updated to: 2022-12-01 | Was: |
| Estimated end date (Changed) | Updated to: 2023-05-12 | Was: 2023-03-10 |
| Actual end date (Changed) | Updated to: 2023-05-11 | Was: |
| Shortage status (Changed) | Updated to: Resolved | Was: Actual shortage |
| Tier 3 Status | No | No |
| Company comments (Changed) | Updated to: Remaining doses are reserved for the public immunization program. Limited quantities available for private orders. | Was: Remaining doses are reserved for the public immunization program. |
| Health Canada comments |